Final guidance on use of axitinib for treating kidney cancer and sipuleucel-T for prostate cancer.
Guidance issued to the NHS today, recommends that the drug axitinib, known as Inlyta by Pfizer, should be available as a second line treatment for kidney cancer.
A separate new guide did not recommended sipuleucel-T, known as Provenge, for treating prostate cancer, because available evidence showed the price to be paid for the drug is too high for the benefit it may provide to patients. …more